Sandborn WJ, Panes J, Danese S, Sharafali Z, et al. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2023;8:43-55.
PMID: 36240801